{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T16:54:18Z","timestamp":1791564858055,"version":"4.3.4"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.ejphar.2026.179312","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T16:10:15Z","timestamp":1788451815000},"page":"179312","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Precision genome editing strategies for enduring lipid lowering in atherosclerosis"],"prefix":"10.1016","volume":"1034","author":[{"given":"Durlav","family":"Chowdhury","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nirdesh","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swarnalata","family":"Garai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devi Prasad","family":"Pandey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9399-8337","authenticated-orcid":false,"given":"Surendra H.","family":"Bodakhe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2026.179312_bib2","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1038\/s41587-020-0561-9","article-title":"Genome editing with CRISPR-cas nucleases, base editors, transposases and prime","volume":"38","author":"Anzalone","year":"2020","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ejphar.2026.179312_bib1","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/s41586-019-1711-4","article-title":"Search-and-replace genome editing without double-strand breaks ordonor DNA","volume":"576","author":"Anzalone","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.ejphar.2026.179312_bib3","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s12915-018-0624-2","article-title":"In vivo genome and base editing of a human PCSK9 knock-in hypercholesterolemic mouse model","volume":"17","author":"Carreras","year":"2019","journal-title":"BMC Biol."},{"key":"10.1016\/j.ejphar.2026.179312_bib4","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1161\/ATVBAHA.117.309881","article-title":"In vivo base editing of PCSK9 (Proprotein convertase subtilisin\/kexin type 9) as a therapeutic alternative to genome editing","volume":"37","author":"Chadwick","year":"2017","journal-title":"ATVB"},{"key":"10.1016\/j.ejphar.2026.179312_bib5","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1146\/annurev-med-112717-094629","article-title":"Ethics of human genome editing","volume":"70","author":"Coller","year":"2019","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.ejphar.2026.179312_bib6","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.ymthe.2019.12.010","article-title":"AAV vector immunogenicity in humans: a long journey to successful gene transfer","volume":"28","author":"Costa Verdera","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ejphar.2026.179312_bib8","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1612790","article-title":"Genetic and pharmacologic inactivation of ANGPTL3 and cardiovascular disease","volume":"377","author":"Dewey","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2026.179312_bib7","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ejphar.2017.05.010","article-title":"Animal models of atherosclerosis","volume":"816","author":"Emini Veseli","year":"2017","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2026.179312_bib9","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1056\/NEJMoa1604304","article-title":"Variation in PCSK9 and HMGCR and risk of cardiovascular disease and diabetes","volume":"375","author":"Ference","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2026.179312_bib10","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/s41565-019-0619-3","article-title":"Pro-efferocytic nanoparticles are specifically taken up by lesional macrophages and prevent atherosclerosis","volume":"15","author":"Flores","year":"2020","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.ejphar.2026.179312_bib11","doi-asserted-by":"crossref","DOI":"10.1101\/pdb.prot086868","article-title":"Adeno-associated virus-mediated delivery of CRISPR-cas systems for genome engineering in mammalian cells","volume":"2016","author":"Gaj","year":"2016","journal-title":"Cold Spring Harb. Protoc."},{"key":"10.1016\/j.ejphar.2026.179312_bib12","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/nature24644","article-title":"Programmable base editing of A\u2022T to G\u2022C in genomic DNA without DNA cleavage","volume":"551","author":"Gaudelli","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.ejphar.2026.179312_bib13","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1056\/NEJMoa2107454","article-title":"CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis","volume":"385","author":"Gillmore","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2026.179312_bib14","doi-asserted-by":"crossref","first-page":"536","DOI":"10.3390\/cells12040536","article-title":"Prime editing for human gene therapy: where are we now?","volume":"12","author":"Godbout","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.ejphar.2026.179312_bib15","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/s41586-019-1161-z","article-title":"Transcriptome-wide off-target RNA editing induced by CRISPR-guided DNA base editors","volume":"569","author":"Gr\u00fcnewald","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.ejphar.2026.179312_bib16","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.3390\/ijms19092721","article-title":"In vivo genome editing as a therapeutic approach","volume":"19","author":"Ho","year":"2018","journal-title":"IJMS"},{"issue":"23","key":"10.1016\/j.ejphar.2026.179312_bib17","doi-asserted-by":"crossref","first-page":"37751","DOI":"10.18632\/oncotarget.17154","article-title":"CRISPR\/Cas9-mediated ApoE-\/- and LDLR-\/- double gene knockout in pigs elevates serum LDL-C and TC levels","volume":"8","author":"Huang","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejphar.2026.179312_bib18","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1038\/s41588-018-0183-z","article-title":"Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations","volume":"50","author":"Khera","year":"2018","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ejphar.2026.179312_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2025.102486","article-title":"Invivo base editing of Angptl3 via lipid nanoparticles to treat cardiovascular disease","volume":"36","author":"Khirallah","year":"2025","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.ejphar.2026.179312_bib20","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1126\/science.aat5011","article-title":"CRISPR-Cas guides the future of genetic engineering","volume":"361","author":"Knott","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.ejphar.2026.179312_bib21","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/nature17946","article-title":"Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage","volume":"533","author":"Komor","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.ejphar.2026.179312_bib22","article-title":"In vitro modeling of atherosclerosis using iPSC-Derived blood vessel organoids","volume":"14","author":"Kong","year":"2024","journal-title":"Adv. Healthcare Mater."},{"key":"10.1016\/j.ejphar.2026.179312_bib23","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/nbt.4192","article-title":"Repair of double-strand breaks induced by CRISPR-Cas9 leads to large deletions and complex rearrangements","volume":"36","author":"Kosicki","year":"2018","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ejphar.2026.179312_bib24","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1038\/s41598-019-38732-2","article-title":"Knockout rat models mimicking human atherosclerosis created by Cpf1-mediated gene targeting","volume":"9","author":"Lee","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejphar.2026.179312_bib25","article-title":"An investigational in vivo base editing medicine targeting ANGPTL3, VERVE-201, achieves potent and LDLR-independent liver editing in mouse models","volume":"44","author":"Lee","year":"2023","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ejphar.2026.179312_bib26","article-title":"In vivo rescue of cardiomyopathy through cardiac prime editing","author":"Liang","year":"2026","journal-title":"bioRxiv"},{"key":"10.1016\/j.ejphar.2026.179312_bib27","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/s41586-021-03392-8","article-title":"The changing landscape of atherosclerosis","volume":"592","author":"Libby","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.ejphar.2026.179312_bib28","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1307095","volume":"371","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.ejphar.2026.179312_bib29","first-page":"16","article-title":"The improvements and applications of prime editing","volume":"6","author":"Lu","year":"2026","journal-title":"DNA (N. Y.)"},{"key":"10.1016\/j.ejphar.2026.179312_bib30","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.tig.2012.03.001","article-title":"Genetics of atherosclerosis","volume":"28","author":"Lusis","year":"2012","journal-title":"Trends Genet."},{"key":"10.1016\/j.ejphar.2026.179312_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.bidere.2026.100073","article-title":"Prime editing: emerging mechanisms, engineering innovations, and next-generation applications","volume":"8","author":"Muhammad","year":"2026","journal-title":"BioDesign Res"},{"key":"10.1016\/j.ejphar.2026.179312_bib32","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/s41586-021-03534-y","article-title":"In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates","volume":"593","author":"Musunuru","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.ejphar.2026.179312_bib33","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.ade1633","article-title":"Precise genomic editing of pathogenic mutations in RBM20 rescues dilated cardiomyopathy","volume":"14","author":"Nishiyama","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ejphar.2026.179312_bib34","series-title":"Lipids and Atherosclerosis","author":"Packard","year":"2005"},{"key":"10.1016\/j.ejphar.2026.179312_bib35","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/s41573-020-0084-6","article-title":"Base editing: advances and therapeutic opportunities","volume":"19","author":"Porto","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejphar.2026.179312_bib36","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2020401118","article-title":"Lipid nanoparticle-mediated codelivery of Cas9 mRNA and single-guide RNA achieves liver-specific in vivo genome editing of Angptl3","volume":"118","author":"Qiu","year":"2021","journal-title":"Proc. Natl. Acad. Sci. U.S.A"},{"key":"10.1016\/j.ejphar.2026.179312_bib37","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/nature14299","article-title":"In vivo genome editing using Staphylococcus aureus Cas9","volume":"520","author":"Ran","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.ejphar.2026.179312_bib38","doi-asserted-by":"crossref","first-page":"7929","DOI":"10.1038\/s41467-022-35604-8","article-title":"A genome-wide CRISPR screen identifies WDFY3 as a regulator of macrophage efferocytosis","volume":"13","author":"Shi","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejphar.2026.179312_bib39","doi-asserted-by":"crossref","DOI":"10.3389\/fgeed.2024.1458037","article-title":"In vivo liver targeted genome editing as therapeutic approach: progresses and challenges","volume":"6","author":"Simoni","year":"2024","journal-title":"Front. Genome Ed."},{"key":"10.1016\/j.ejphar.2026.179312_bib40","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.jconrel.2024.04.022","article-title":"Lipid nanoparticle-based strategies for extrahepatic delivery of nucleic acid therapies - challenges and opportunities","volume":"370","author":"Simonsen","year":"2024","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.ejphar.2026.179312_bib41","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1093\/eurheartj\/ehu058","article-title":"Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype-phenotype relationship, and clinical outcome","volume":"36","author":"Sjouke","year":"2014","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ejphar.2026.179312_bib42","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.jacc.2016.11.042","article-title":"A Test in context: lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies","volume":"69","author":"Tsimikas","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ejphar.2026.179312_bib43","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.cmet.2016.11.001","article-title":"Applications and limitations of mouse models for understanding human atherosclerosis","volume":"25","author":"Von Scheidt","year":"2016","journal-title":"Cell Metab."},{"key":"10.1016\/j.ejphar.2026.179312_bib44","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/s41573-019-0012-9","article-title":"Adeno-associated virus vector as a platform for gene therapy delivery","volume":"18","author":"Wang","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejphar.2026.179312_bib45","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1010680","article-title":"Multimodal CRISPR perturbations of GWAS loci associated with coronary artery disease in vascular endothelial cells","volume":"19","author":"W\u00fcnnemann","year":"2023","journal-title":"PLoS Genet."},{"key":"10.1016\/j.ejphar.2026.179312_bib46","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/nbt.3471","article-title":"Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo","volume":"34","author":"Yin","year":"2016","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ejphar.2026.179312_bib47","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.tcm.2020.06.008","article-title":"Translating genomic insights into cardiovascular medicine: opportunities and challenges of CRISPR-Cas9","volume":"31","author":"Zhang","year":"2020","journal-title":"Trends Cardiovasc. Med."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299926007946?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299926007946?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T16:17:57Z","timestamp":1791562677000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299926007946"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":47,"alternative-id":["S0014299926007946"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2026.179312","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Precision genome editing strategies for enduring lipid lowering in atherosclerosis","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2026.179312","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"179312"}}